FDA To Internal Tissue Adhesive Firms: Come In Early With Details
This article was originally published in The Gray Sheet
Device firms developing new internal tissue adhesive products should meet with the agency early on and provide detailed descriptions of their product and clinical protocol, agency officials said at a recent meeting.
You may also be interested in...
Based on discussions at a recent workshop, FDA sees "multiple opportunities for guidance" on internal tissue adhesives, an agency official said.
Fujifilm’s Aspire HD gains FDA clearance
FDA closes underused pilot Multipurpose Audit Program